Previous close | 129.67 |
Open | 129.67 |
Bid | 110.00 |
Ask | 119.00 |
Strike | 160.00 |
Expiry date | 2026-01-16 |
Day's range | 129.67 - 129.67 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
Biogen stock jumped early Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.